The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells

BACKGROUND: The lack of drug targets is an obstacle to the treatment of patients with triple-negative breast cancer (TNBC). At present, non-specific cytotoxic drugs are first-line agents, but the development of resistance is a major problem with these agents. The epidermal growth factor receptor (EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Stanton, Al-Zubaidi, Yassir, Rahman, Md Khalilur, Bourget, Kirsi, Zhou, Fanfan, Murray, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584993/
https://www.ncbi.nlm.nih.gov/pubmed/35908023
http://dx.doi.org/10.1007/s43440-022-00396-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584993/
https://www.ncbi.nlm.nih.gov/pubmed/35908023
http://dx.doi.org/10.1007/s43440-022-00396-7

Ejemplares similares